RxDoctor Payments Data

Nadia Javaid, MD

Family Medicine · Fresno, CANPI 1023429412

Payments from drug & device makers

$2,258in general payments, 2019–2025

Across 123 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$345
  • Novo Nordisk$338
  • AbbVie$296
  • Lilly USA, LLC$281
  • Pfizer$126
  • Boehringer Ingelheim$115
  • plus $760 from 18 others

What the payments were for

  • Food & beverage$2,24799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,258 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$93,140
Medicare patients
203
Services billed
1,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$91,683
TrulicityDulaglutide45$60,391
MounjaroTirzepatide43$43,472
FarxigaDapagliflozin Propanediol32$39,614
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$30,078
EliquisApixaban11$19,461
JardianceEmpagliflozin11$19,176
JanumetSitagliptin Phos/Metformin Hcl13$15,406
Breo ElliptaFluticasone/Vilanterol22$13,382
VascepaIcosapent Ethyl16$12,323
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,413
Praluent PenAlirocumab11$5,468
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,568
SymbicortBudesonide/Formoterol Fumarate18$4,192
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$281$103,86388 claims
Novo NordiskOzempic$338$91,68364 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$51$49,87376 claims
AstraZenecaFarxiga, Symbicort$345$43,80550 claims
PfizerEliquis$126$19,46111 claims
Boehringer IngelheimJardiance$115$19,17611 claims
MerckJanumet$72$15,40613 claims
AbbVieSynthroid$296$1,04413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →